Join the newsletter that everyone in finance secretly reads. 1M+ subscribers, 100% free.

Addus HomeCare topped analyst forecasts for both revenue and earnings this quarter, while picking up steam with fresh acquisitions across the US.

What does this mean?

Addus HomeCare saw net service revenue climb to $349.4 million -- a jump of nearly 22% from last year -- driven by organic growth and deals like the Helping Hands Home Care buyout. Adjusted earnings per share landed at $1.49, nudging past analyst expectations, while adjusted net income reached $27.3 million. Expansion into new states, plus the integration of Gentiva operations, highlights Addus's strategy of balancing organic growth with targeted acquisitions. Personal care and hospice segments stood out, logging 7.4% and 10% organic growth, fueled by rising patient volumes and improved reimbursement rates. With $22.5 million in operating cash flow and a cautious balance sheet, Addus is well-positioned for more acquisitions and continued home-based care momentum.

Addus shares are still trading just below sector averages -- resting at a price-to-earnings ratio of 16, down a notch from 17 three months back. But analysts are upbeat: 11 out of 12 rate Addus a 'buy' or 'strong buy,' and Wall Street's median target implies about 25% upside from current prices. Healthcare facilities stocks more broadly carry a 'buy' consensus, with continued investor interest as demographics and new healthcare policies fuel steady long-term growth.

The bigger picture: Healthcare shifts home as demand climbs.

Addus's results underscore a major transformation in US healthcare -- one where aging populations and changing policies push more care into patients' homes. The company's stable, disciplined expansion mirrors a broader industry pivot toward at-home care. As payers and patients increasingly prefer these services, providers with broad footprints and solid finances are set to lead the next era in healthcare -- not just keep pace.